Annual revenue was KRW 10.8 billion in 2022, KRW 10.8 billion in 2023 (down 0.1% year on year), KRW 6.07 billion in 2024 (down 43.6%), and KRW 5.35 billion in 2025 (down 11.9%), a decline for three consecutive years from 2023 through 2025. Among the years from 2022 to 2025, 2022 was the largest and 2025 the smallest.
The operating loss widened from KRW 3.67 billion in 2022 to KRW 11.2 billion in 2023, KRW 22.7 billion in 2024, and KRW 24.5 billion in 2025, a loss in each of four consecutive years from 2022 through 2025. The operating margin deteriorated from -34.0% in 2022 to -103.8% in 2023, -373.6% in 2024, and -457.4% in 2025.
The net loss attributable to controlling shareholders widened from KRW 2.28 billion in 2022 to KRW 8.11 billion in 2023, KRW 19.1 billion in 2024, and KRW 23.1 billion in 2025, and the consolidated net loss including non-controlling interests was reported at the same amounts.
Margin pressure has come from R&D costs hitting the income statement in full while revenue shrank. The company expenses all development costs rather than capitalizing them, and first-half 2026 R&D spending was KRW 12 billion, equal to 105.2% of revenue (Bloter report).
Quarterly revenue went from KRW 842 million in Q3 2025 to KRW 1.71 billion in Q4 2025, KRW 5.15 billion in Q1 2026, and KRW 6.34 billion in Q2 2026, then fell 46.5% quarter on quarter to KRW 3.4 billion in Q3 2026.
The operating loss narrowed from KRW 6.57 billion in Q3 2025 to KRW 865 million in Q2 2026, then widened to KRW 5.97 billion in Q3 2026. The company has reported losses for five consecutive quarters, from Q3 2025 through Q3 2026.
The net loss attributable to controlling shareholders was KRW 5.88 billion in Q3 2026, and the total for the last four quarters, from Q4 2025 through Q3 2026, was KRW 19.7 billion. Total equity at year-end 2025 was KRW 36.3 billion and total liabilities were KRW 46.7 billion, a debt ratio of 128.6%.